Buprenorphine keeps millions of people alive and stable. For some, it also becomes the hardest thing they have ever tried to stop taking. Here is what ibogaine can and cannot do about that — and the one clinical fact every clinic will tell you before anything else.
Published 27 August 2026 · Last updated 8 September 2026 · Clinically reviewed by Christopher Diviaio, LCSW
It acts on the same receptor system buprenorphine occupies. Dosed at the right point against your last dose — timing the clinic plans during intake, not something you work out yourself — people report little to no physical withdrawal.
Buprenorphine is a partial agonist with unusually high affinity for the mu-opioid receptor. It occupies the receptor firmly and leaves slowly. That combination is exactly why it works as maintenance — it blocks withdrawal and blunts cravings for a full day or more — and it is the same reason coming off it can stretch out over weeks instead of days.
That same property is why the timing of treatment matters so much, and why a competent clinic plans it from your history rather than leaving it to you. Get it right and the transition is far gentler than the taper most people are dreading.
Price alone tells you almost nothing. These four things separate a medical program from a retreat with a doctor on call, and every one of them should be named in writing before you pay a deposit.
Bloodwork, ECG, medication review and a full medical history, taken before you travel. This is where anything that needs discussing gets found and discussed.
Intake that maps your history and plans the timing of the dose against your current medication. That is the clinic’s job, and it is the difference between a comfortable transition and a miserable one.
Continuous monitoring through the treatment itself, with medical staff present in the room rather than on call from elsewhere.
A named plan for the weeks that follow. The window this opens is the opportunity; what fills it decides whether it holds.
We would rather under-claim than sell you something. Here is the state of the literature, with the study design attached to every number, because a number without its design is marketing.
Ibogaine reduces heroin and opioid cravings by upwards of 50%, for up to 24 weeks. American Journal of Therapeutics, 2024 — peer-reviewed clinical primer.
Only one double-blind placebo-controlled trial of ibogaine exists. American Journal of Therapeutics, 2024. Everything else is weaker evidence.
In 30 veterans with traumatic brain injury, magnesium-ibogaine produced large improvements in functioning, PTSD, depression and anxiety at one month. Nature Medicine, 2024 — observational, open-label, no control group. Not an opioid-dependence study.
That same study reported no unexpected or serious adverse events across the cohort.
There is no large randomised controlled trial of ibogaine for buprenorphine dependence. Anyone who tells you the science is settled is not reading the same papers.
It acts on the same mu-opioid receptor system buprenorphine occupies. Dosed at the right point against your last dose — timing the clinic plans during intake — people report little to no physical withdrawal. Its long-lived metabolite, noribogaine, is the proposed basis for the reduced cravings that follow.
Buprenorphine binds mu-opioid receptors very tightly and clears slowly. That is exactly what makes it effective for maintenance, and it is also why tapering can drag on for weeks rather than days. It is a pharmacological property, not a failure of willpower.
No. Planning the timing against your current medication is the clinic’s job and it is what intake exists for. Any competent program maps it from your history before you travel; one that leaves it to you is telling you something about itself.
Seven to fourteen days, covering intake and screening, the treatment day, and a monitored recovery period. Seven is the floor rather than the target — leaving earlier means leaving in the middle of the part that does the work.
The evidence is early. A 2024 peer-reviewed primer in the American Journal of Therapeutics reports ibogaine reduces heroin and opioid cravings by upwards of 50%, for up to 24 weeks, and states plainly that only one double-blind placebo-controlled trial of ibogaine exists. Most of the literature is open-label and observational, so it cannot establish efficacy on its own.
No. Ibogaine is Schedule I in the US. It is not scheduled in Mexico and several other countries, which is where medically supervised programs operate and where US patients travel.
Programs generally run $5,000 to $15,000 depending on length of stay and facility. Ask for the full, itemised program cost rather than a per-day rate, and confirm that screening, monitoring and aftercare are included.
More on how ibogaine works, the wider picture on addiction and psychedelic-assisted treatment, what opioid detox involves, and what treatment actually costs. Every program we discuss is measured against the Psychedelic Connect Standard.
Last updated 26 August 2026 · Written and clinically reviewed by Christopher Diviaio, LCSW · Educational, not medical advice.
We hold every clinic we recommend to our published standard and we will tell you when the answer is no. Confidential, client-first, and educational — not medical advice. Call or text (866) 435-7057.
Speak with an advisor →